Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of Daratumumab in MRD-positive multiple myeloma with ≥VGPR
2018-000386-36Phase 2Completed
- Sponsor
- Azienda Ospedaliera Universitaria Senese
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Azienda Ospedaliera Universitaria Senese. Primary endpoints: Minimal residual disease (MRD) negativity rate over time and Acute and late toxicity rate. Started Feb 2021; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-000386-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000386-36.